Report cover image

Central Lab Market By Services (Genetic services, Biomarker services, Anatomic pathology and histology, Specimen management and storage, Others), By End user (Pharmaceutical companies, Biotechnology companies, Others): Global Opportunity Analysis and Indu

Publisher Allied Market Research
Published Mar 01, 2023
Length 223 Pages
SKU # ALMR18022773

Description

Central Lab Market By Services (Genetic services, Biomarker services, Anatomic pathology and histology, Specimen management and storage, Others), By End user (Pharmaceutical companies, Biotechnology companies, Others): Global Opportunity Analysis and Industry Forecast, 2022-2031


The global central lab market was valued at $3.3 billion in 2021, and is projected to reach $6 billion by 2031, growing at a CAGR of 6% from 2022 to 2031. A central lab is a laboratory/institution responsible for laboratory assessments, providing services from conducting laboratory assessments and compiling lab test reports to contracting courier services for delivering lab kits and bio samples from or to medical institutions. In addition, central labs offer standardized in-house methods of testing for clinical trials, ensuring validity of results and consistency in interpretation throughout the trial.

Furthermore, central labs carry out laboratory tests requested by the sponsor using validated machinery, standardized methods, reference ranges, and trial-specific testing kits. Thus, central labs ensure consistent results, analyses, and are also equipped with modern electronic data storage & transmission facilities. 

The major factors driving the growth of the central lab market are increase in number of clinical trials, rise in demand for novel drugs, and various technological advancements enabling central labs to offer wide range of services. The demand for clinical trials has been steadily growing, driven by the need for new drugs, medical devices and treatments to address a wide range of diseases and conditions. Thus, central labs play a vital role in supporting clinical trials, providing essential testing and analysis services to help to evaluate the safety and efficacy of new drugs. In addition, advances in technology have enabled central labs to offer a wider range of services, including the analysis of biomarkers, pharmacokinetics (PK), and pharmacodynamics (PD) testing, and other laboratory tests that are required to evaluate the safety and efficacy of new drugs.

These advances have improved the accuracy and speed of testing services, which has increased demand for central lab services driving the growth of the market. Moreover, biomarker services are a key area of expertise of central lab, as it plays a critical role in supporting biomarker research by providing a range of testing and analysis services to measure biomarkers in various biological matrices. Central labs can develop and validate new biomarker assays, provide specialized sample analysis services, and offer data analysis and consulting services to support drug development and clinical research studies. 

Furthermore, increase in number of key players offering such services and rise in launch of new services is expected to drive the growth of market. For instance, in October 2022, Q2 Solutions, (a wholly owned subsidiary of IQVIA) and a leading global clinical trial laboratory services organization, announced the launch of the first self-collection safety lab panel for U.S. clinical trial participants offering combined industry leading laboratory services, patient focused logistics, and cutting-edge, self-collection technology. Thus, such launches by key players of the market are expected to propel the market expansion. 

The global central lab market is segmented into services, end user, and region. On the basis of services, the market is divided into genetic services, biomarker services, anatomic pathology and histology, specimen management and storage, and others. On the basis of end user, the market is categorized into pharmaceutical companies, biotechnology companies, and others. Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA). 

Major key players that operate in the global central lab market are Laboratory Corporation of America, Rochester Regional Health (ACM Global Laboratories), ICON plc, Medpace, IQVIA Inc (Q2 Solutions), Eurofins Scientific, LabConnect, Cerba HealthCare (Cerba Research), Frontage Labs, and CIRION BioPharma Research Inc.

Key Benefits For Stakeholders

This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the central lab market analysis from 2021 to 2031 to identify the prevailing central lab market opportunities.
The market research is offered along with information related to key drivers, restraints, and opportunities.
Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
In-depth analysis of the central lab market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
The report includes the analysis of the regional as well as global central lab market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By End user

Pharmaceutical companies
Biotechnology companies
Others

By Services

Genetic services
Biomarker services
Anatomic pathology and histology
Specimen management and storage
Others

By Region

North America
U.S.
Canada
Mexico
Europe
Germany
France
UK
Italy
Spain
Rest of Europe
Asia-Pacific
Japan
China
India
Australia
South Korea
Rest of Asia-Pacific
LAMEA
Brazil
Saudi Arabia
South Africa
Rest of LAMEA
Key Market Players
Eurofins Scientific
ICON Plc
IQVIA Inc.
Frontage Labs
CIRION BioPharma Research Inc.
Rochester Regional Health
LabConnect
Cerba Healthcare
Laboratory Corporation of America Holdings
Medpace

Please Note: It will take 7-10 business days to complete the report upon order confirmation.

Table of Contents

223 Pages
CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research Methodology
1.4.1. Primary research
1.4.2. Secondary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO Perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top impacting factors
3.2.2. Top investment pockets
3.3. Porter’s five forces analysis
3.3.1. Bargaining power of suppliers
3.3.2. Bargaining power of buyers
3.3.3. Threat of substitutes
3.3.4. Threat of new entrants
3.3.5. Intensity of rivalry
3.4. Market dynamics
3.4.1. Drivers
3.4.1.1. Rising investments in R&D and clinical trials
3.4.1.2. Rise in adoption of outsourcing of central lab
3.4.1.3. Increase in demand for novel drugs
3.4.2. Restraints
3.4.2.1. Issues with logistics and sample handling
3.4.3. Opportunities
3.4.3.1. Growth opportunities in emerging markets
3.5. COVID-19 Impact Analysis on the market
CHAPTER 4: CENTRAL LAB MARKET, BY SERVICES
4.1. Overview
4.1.1. Market size and forecast
4.2. Genetic services
4.2.1. Key market trends, growth factors and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market share analysis by country
4.3. Biomarker services
4.3.1. Key market trends, growth factors and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market share analysis by country
4.4. Anatomic pathology and histology
4.4.1. Key market trends, growth factors and opportunities
4.4.2. Market size and forecast, by region
4.4.3. Market share analysis by country
4.5. Specimen management and storage
4.5.1. Key market trends, growth factors and opportunities
4.5.2. Market size and forecast, by region
4.5.3. Market share analysis by country
4.6. Others
4.6.1. Key market trends, growth factors and opportunities
4.6.2. Market size and forecast, by region
4.6.3. Market share analysis by country
CHAPTER 5: CENTRAL LAB MARKET, BY END USER
5.1. Overview
5.1.1. Market size and forecast
5.2. Pharmaceutical companies
5.2.1. Key market trends, growth factors and opportunities
5.2.2. Market size and forecast, by region
5.2.3. Market share analysis by country
5.3. Biotechnology companies
5.3.1. Key market trends, growth factors and opportunities
5.3.2. Market size and forecast, by region
5.3.3. Market share analysis by country
5.4. Others
5.4.1. Key market trends, growth factors and opportunities
5.4.2. Market size and forecast, by region
5.4.3. Market share analysis by country
CHAPTER 6: CENTRAL LAB MARKET, BY REGION
6.1. Overview
6.1.1. Market size and forecast By Region
6.2. North America
6.2.1. Key trends and opportunities
6.2.2. Market size and forecast, by Services
6.2.3. Market size and forecast, by End user
6.2.4. Market size and forecast, by country
6.2.4.1. U.S.
6.2.4.1.1. Key market trends, growth factors and opportunities
6.2.4.1.2. Market size and forecast, by Services
6.2.4.1.3. Market size and forecast, by End user
6.2.4.2. Canada
6.2.4.2.1. Key market trends, growth factors and opportunities
6.2.4.2.2. Market size and forecast, by Services
6.2.4.2.3. Market size and forecast, by End user
6.2.4.3. Mexico
6.2.4.3.1. Key market trends, growth factors and opportunities
6.2.4.3.2. Market size and forecast, by Services
6.2.4.3.3. Market size and forecast, by End user
6.3. Europe
6.3.1. Key trends and opportunities
6.3.2. Market size and forecast, by Services
6.3.3. Market size and forecast, by End user
6.3.4. Market size and forecast, by country
6.3.4.1. Germany
6.3.4.1.1. Key market trends, growth factors and opportunities
6.3.4.1.2. Market size and forecast, by Services
6.3.4.1.3. Market size and forecast, by End user
6.3.4.2. France
6.3.4.2.1. Key market trends, growth factors and opportunities
6.3.4.2.2. Market size and forecast, by Services
6.3.4.2.3. Market size and forecast, by End user
6.3.4.3. UK
6.3.4.3.1. Key market trends, growth factors and opportunities
6.3.4.3.2. Market size and forecast, by Services
6.3.4.3.3. Market size and forecast, by End user
6.3.4.4. Italy
6.3.4.4.1. Key market trends, growth factors and opportunities
6.3.4.4.2. Market size and forecast, by Services
6.3.4.4.3. Market size and forecast, by End user
6.3.4.5. Spain
6.3.4.5.1. Key market trends, growth factors and opportunities
6.3.4.5.2. Market size and forecast, by Services
6.3.4.5.3. Market size and forecast, by End user
6.3.4.6. Rest of Europe
6.3.4.6.1. Key market trends, growth factors and opportunities
6.3.4.6.2. Market size and forecast, by Services
6.3.4.6.3. Market size and forecast, by End user
6.4. Asia-Pacific
6.4.1. Key trends and opportunities
6.4.2. Market size and forecast, by Services
6.4.3. Market size and forecast, by End user
6.4.4. Market size and forecast, by country
6.4.4.1. Japan
6.4.4.1.1. Key market trends, growth factors and opportunities
6.4.4.1.2. Market size and forecast, by Services
6.4.4.1.3. Market size and forecast, by End user
6.4.4.2. China
6.4.4.2.1. Key market trends, growth factors and opportunities
6.4.4.2.2. Market size and forecast, by Services
6.4.4.2.3. Market size and forecast, by End user
6.4.4.3. India
6.4.4.3.1. Key market trends, growth factors and opportunities
6.4.4.3.2. Market size and forecast, by Services
6.4.4.3.3. Market size and forecast, by End user
6.4.4.4. Australia
6.4.4.4.1. Key market trends, growth factors and opportunities
6.4.4.4.2. Market size and forecast, by Services
6.4.4.4.3. Market size and forecast, by End user
6.4.4.5. South Korea
6.4.4.5.1. Key market trends, growth factors and opportunities
6.4.4.5.2. Market size and forecast, by Services
6.4.4.5.3. Market size and forecast, by End user
6.4.4.6. Rest of Asia-Pacific
6.4.4.6.1. Key market trends, growth factors and opportunities
6.4.4.6.2. Market size and forecast, by Services
6.4.4.6.3. Market size and forecast, by End user
6.5. LAMEA
6.5.1. Key trends and opportunities
6.5.2. Market size and forecast, by Services
6.5.3. Market size and forecast, by End user
6.5.4. Market size and forecast, by country
6.5.4.1. Brazil
6.5.4.1.1. Key market trends, growth factors and opportunities
6.5.4.1.2. Market size and forecast, by Services
6.5.4.1.3. Market size and forecast, by End user
6.5.4.2. Saudi Arabia
6.5.4.2.1. Key market trends, growth factors and opportunities
6.5.4.2.2. Market size and forecast, by Services
6.5.4.2.3. Market size and forecast, by End user
6.5.4.3. South Africa
6.5.4.3.1. Key market trends, growth factors and opportunities
6.5.4.3.2. Market size and forecast, by Services
6.5.4.3.3. Market size and forecast, by End user
6.5.4.4. Rest of LAMEA
6.5.4.4.1. Key market trends, growth factors and opportunities
6.5.4.4.2. Market size and forecast, by Services
6.5.4.4.3. Market size and forecast, by End user
CHAPTER 7: COMPETITIVE LANDSCAPE
7.1. Introduction
7.2. Top winning strategies
7.3. Product Mapping of Top 10 Player
7.4. Competitive Dashboard
7.5. Competitive Heatmap
7.6. Top player positioning, 2021
CHAPTER 8: COMPANY PROFILES
8.1. Eurofins Scientific
8.1.1. Company overview
8.1.2. Key Executives
8.1.3. Company snapshot
8.1.4. Operating business segments
8.1.5. Product portfolio
8.1.6. Business performance
8.1.7. Key strategic moves and developments
8.2. ICON Plc
8.2.1. Company overview
8.2.2. Key Executives
8.2.3. Company snapshot
8.2.4. Operating business segments
8.2.5. Product portfolio
8.2.6. Business performance
8.2.7. Key strategic moves and developments
8.3. Medpace
8.3.1. Company overview
8.3.2. Key Executives
8.3.3. Company snapshot
8.3.4. Operating business segments
8.3.5. Product portfolio
8.3.6. Business performance
8.4. Rochester Regional Health
8.4.1. Company overview
8.4.2. Key Executives
8.4.3. Company snapshot
8.4.4. Operating business segments
8.4.5. Product portfolio
8.5. IQVIA Inc.
8.5.1. Company overview
8.5.2. Key Executives
8.5.3. Company snapshot
8.5.4. Operating business segments
8.5.5. Product portfolio
8.5.6. Business performance
8.5.7. Key strategic moves and developments
8.6. LabConnect
8.6.1. Company overview
8.6.2. Key Executives
8.6.3. Company snapshot
8.6.4. Operating business segments
8.6.5. Product portfolio
8.7. Cerba Healthcare
8.7.1. Company overview
8.7.2. Key Executives
8.7.3. Company snapshot
8.7.4. Operating business segments
8.7.5. Product portfolio
8.7.6. Key strategic moves and developments
8.8. Frontage Labs
8.8.1. Company overview
8.8.2. Key Executives
8.8.3. Company snapshot
8.8.4. Operating business segments
8.8.5. Product portfolio
8.8.6. Business performance
8.8.7. Key strategic moves and developments
8.9. CIRION BioPharma Research Inc.
8.9.1. Company overview
8.9.2. Key Executives
8.9.3. Company snapshot
8.9.4. Operating business segments
8.9.5. Product portfolio
8.10. Laboratory Corporation of America Holdings
8.10.1. Company overview
8.10.2. Key Executives
8.10.3. Company snapshot
8.10.4. Operating business segments
8.10.5. Product portfolio
8.10.6. Business performance
8.10.7. Key strategic moves and developments
LIST OF TABLES
TABLE 01. GLOBAL CENTRAL LAB MARKET, BY SERVICES, 2021-2031 ($MILLION)
TABLE 02. CENTRAL LAB MARKET FOR GENETIC SERVICES, BY REGION, 2021-2031 ($MILLION)
TABLE 03. CENTRAL LAB MARKET FOR BIOMARKER SERVICES, BY REGION, 2021-2031 ($MILLION)
TABLE 04. CENTRAL LAB MARKET FOR ANATOMIC PATHOLOGY AND HISTOLOGY, BY REGION, 2021-2031 ($MILLION)
TABLE 05. CENTRAL LAB MARKET FOR SPECIMEN MANAGEMENT AND STORAGE, BY REGION, 2021-2031 ($MILLION)
TABLE 06. CENTRAL LAB MARKET FOR OTHERS, BY REGION, 2021-2031 ($MILLION)
TABLE 07. GLOBAL CENTRAL LAB MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 08. CENTRAL LAB MARKET FOR PHARMACEUTICAL COMPANIES, BY REGION, 2021-2031 ($MILLION)
TABLE 09. CENTRAL LAB MARKET FOR BIOTECHNOLOGY COMPANIES, BY REGION, 2021-2031 ($MILLION)
TABLE 10. CENTRAL LAB MARKET FOR OTHERS, BY REGION, 2021-2031 ($MILLION)
TABLE 11. CENTRAL LAB MARKET, BY REGION, 2021-2031 ($MILLION)
TABLE 12. NORTH AMERICA CENTRAL LAB MARKET, BY SERVICES, 2021-2031 ($MILLION)
TABLE 13. NORTH AMERICA CENTRAL LAB MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 14. NORTH AMERICA CENTRAL LAB MARKET, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 15. U.S. CENTRAL LAB MARKET, BY SERVICES, 2021-2031 ($MILLION)
TABLE 16. U.S. CENTRAL LAB MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 17. CANADA CENTRAL LAB MARKET, BY SERVICES, 2021-2031 ($MILLION)
TABLE 18. CANADA CENTRAL LAB MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 19. MEXICO CENTRAL LAB MARKET, BY SERVICES, 2021-2031 ($MILLION)
TABLE 20. MEXICO CENTRAL LAB MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 21. EUROPE CENTRAL LAB MARKET, BY SERVICES, 2021-2031 ($MILLION)
TABLE 22. EUROPE CENTRAL LAB MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 23. EUROPE CENTRAL LAB MARKET, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 24. GERMANY CENTRAL LAB MARKET, BY SERVICES, 2021-2031 ($MILLION)
TABLE 25. GERMANY CENTRAL LAB MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 26. FRANCE CENTRAL LAB MARKET, BY SERVICES, 2021-2031 ($MILLION)
TABLE 27. FRANCE CENTRAL LAB MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 28. UK CENTRAL LAB MARKET, BY SERVICES, 2021-2031 ($MILLION)
TABLE 29. UK CENTRAL LAB MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 30. ITALY CENTRAL LAB MARKET, BY SERVICES, 2021-2031 ($MILLION)
TABLE 31. ITALY CENTRAL LAB MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 32. SPAIN CENTRAL LAB MARKET, BY SERVICES, 2021-2031 ($MILLION)
TABLE 33. SPAIN CENTRAL LAB MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 34. REST OF EUROPE CENTRAL LAB MARKET, BY SERVICES, 2021-2031 ($MILLION)
TABLE 35. REST OF EUROPE CENTRAL LAB MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 36. ASIA-PACIFIC CENTRAL LAB MARKET, BY SERVICES, 2021-2031 ($MILLION)
TABLE 37. ASIA-PACIFIC CENTRAL LAB MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 38. ASIA-PACIFIC CENTRAL LAB MARKET, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 39. JAPAN CENTRAL LAB MARKET, BY SERVICES, 2021-2031 ($MILLION)
TABLE 40. JAPAN CENTRAL LAB MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 41. CHINA CENTRAL LAB MARKET, BY SERVICES, 2021-2031 ($MILLION)
TABLE 42. CHINA CENTRAL LAB MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 43. INDIA CENTRAL LAB MARKET, BY SERVICES, 2021-2031 ($MILLION)
TABLE 44. INDIA CENTRAL LAB MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 45. AUSTRALIA CENTRAL LAB MARKET, BY SERVICES, 2021-2031 ($MILLION)
TABLE 46. AUSTRALIA CENTRAL LAB MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 47. SOUTH KOREA CENTRAL LAB MARKET, BY SERVICES, 2021-2031 ($MILLION)
TABLE 48. SOUTH KOREA CENTRAL LAB MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 49. REST OF ASIA-PACIFIC CENTRAL LAB MARKET, BY SERVICES, 2021-2031 ($MILLION)
TABLE 50. REST OF ASIA-PACIFIC CENTRAL LAB MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 51. LAMEA CENTRAL LAB MARKET, BY SERVICES, 2021-2031 ($MILLION)
TABLE 52. LAMEA CENTRAL LAB MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 53. LAMEA CENTRAL LAB MARKET, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 54. BRAZIL CENTRAL LAB MARKET, BY SERVICES, 2021-2031 ($MILLION)
TABLE 55. BRAZIL CENTRAL LAB MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 56. SAUDI ARABIA CENTRAL LAB MARKET, BY SERVICES, 2021-2031 ($MILLION)
TABLE 57. SAUDI ARABIA CENTRAL LAB MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 58. SOUTH AFRICA CENTRAL LAB MARKET, BY SERVICES, 2021-2031 ($MILLION)
TABLE 59. SOUTH AFRICA CENTRAL LAB MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 60. REST OF LAMEA CENTRAL LAB MARKET, BY SERVICES, 2021-2031 ($MILLION)
TABLE 61. REST OF LAMEA CENTRAL LAB MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 62. EUROFINS SCIENTIFIC: KEY EXECUTIVES
TABLE 63. EUROFINS SCIENTIFIC: COMPANY SNAPSHOT
TABLE 64. EUROFINS SCIENTIFIC: SERVICE SEGMENTS
TABLE 65. EUROFINS SCIENTIFIC: PRODUCT PORTFOLIO
TABLE 66. EUROFINS SCIENTIFIC: KEY STRATERGIES
TABLE 67. ICON PLC: KEY EXECUTIVES
TABLE 68. ICON PLC: COMPANY SNAPSHOT
TABLE 69. ICON PLC: SERVICE SEGMENTS
TABLE 70. ICON PLC: PRODUCT PORTFOLIO
TABLE 71. ICON PLC: KEY STRATERGIES
TABLE 72. MEDPACE: KEY EXECUTIVES
TABLE 73. MEDPACE: COMPANY SNAPSHOT
TABLE 74. MEDPACE: SERVICE SEGMENTS
TABLE 75. MEDPACE: PRODUCT PORTFOLIO
TABLE 76. ROCHESTER REGIONAL HEALTH: KEY EXECUTIVES
TABLE 77. ROCHESTER REGIONAL HEALTH: COMPANY SNAPSHOT
TABLE 78. ROCHESTER REGIONAL HEALTH: SERVICE SEGMENTS
TABLE 79. ROCHESTER REGIONAL HEALTH: PRODUCT PORTFOLIO
TABLE 80. IQVIA INC.: KEY EXECUTIVES
TABLE 81. IQVIA INC.: COMPANY SNAPSHOT
TABLE 82. IQVIA INC.: SERVICE SEGMENTS
TABLE 83. IQVIA INC.: PRODUCT PORTFOLIO
TABLE 84. IQVIA INC.: KEY STRATERGIES
TABLE 85. LABCONNECT: KEY EXECUTIVES
TABLE 86. LABCONNECT: COMPANY SNAPSHOT
TABLE 87. LABCONNECT: SERVICE SEGMENTS
TABLE 88. LABCONNECT: PRODUCT PORTFOLIO
TABLE 89. CERBA HEALTHCARE: KEY EXECUTIVES
TABLE 90. CERBA HEALTHCARE: COMPANY SNAPSHOT
TABLE 91. CERBA HEALTHCARE: SERVICE SEGMENTS
TABLE 92. CERBA HEALTHCARE: PRODUCT PORTFOLIO
TABLE 93. CERBA HEALTHCARE: KEY STRATERGIES
TABLE 94. FRONTAGE LABS: KEY EXECUTIVES
TABLE 95. FRONTAGE LABS: COMPANY SNAPSHOT
TABLE 96. FRONTAGE LABS: SERVICE SEGMENTS
TABLE 97. FRONTAGE LABS: PRODUCT PORTFOLIO
TABLE 98. FRONTAGE LABS: KEY STRATERGIES
TABLE 99. CIRION BIOPHARMA RESEARCH INC.: KEY EXECUTIVES
TABLE 100. CIRION BIOPHARMA RESEARCH INC.: COMPANY SNAPSHOT
TABLE 101. CIRION BIOPHARMA RESEARCH INC.: SERVICE SEGMENTS
TABLE 102. CIRION BIOPHARMA RESEARCH INC.: PRODUCT PORTFOLIO
TABLE 103. LABORATORY CORPORATION OF AMERICA HOLDINGS: KEY EXECUTIVES
TABLE 104. LABORATORY CORPORATION OF AMERICA HOLDINGS: COMPANY SNAPSHOT
TABLE 105. LABORATORY CORPORATION OF AMERICA HOLDINGS: PRODUCT SEGMENTS
TABLE 106. LABORATORY CORPORATION OF AMERICA HOLDINGS: PRODUCT PORTFOLIO
TABLE 107. LABORATORY CORPORATION OF AMERICA HOLDINGS: KEY STRATERGIES
LIST OF FIGURES
FIGURE 01. CENTRAL LAB MARKET, 2021-2031
FIGURE 02. SEGMENTATION OF CENTRAL LAB MARKET, 2021-2031
FIGURE 03. TOP INVESTMENT POCKETS IN CENTRAL LAB MARKET (2022-2031)
FIGURE 04. LOW BARGAINING POWER OF SUPPLIERS
FIGURE 05. LOW BARGAINING POWER OF BUYERS
FIGURE 06. LOW THREAT OF SUBSTITUTES
FIGURE 07. LOW THREAT OF NEW ENTRANTS
FIGURE 08. LOW INTENSITY OF RIVALRY
FIGURE 09. DRIVERS, RESTRAINTS AND OPPORTUNITIES: GLOBALCENTRAL LAB MARKET
FIGURE 10. CENTRAL LAB MARKET, BY SERVICES, 2021(%)
FIGURE 11. COMPARATIVE SHARE ANALYSIS OF CENTRAL LAB MARKET FOR GENETIC SERVICES, BY COUNTRY 2021 AND 2031(%)
FIGURE 12. COMPARATIVE SHARE ANALYSIS OF CENTRAL LAB MARKET FOR BIOMARKER SERVICES, BY COUNTRY 2021 AND 2031(%)
FIGURE 13. COMPARATIVE SHARE ANALYSIS OF CENTRAL LAB MARKET FOR ANATOMIC PATHOLOGY AND HISTOLOGY, BY COUNTRY 2021 AND 2031(%)
FIGURE 14. COMPARATIVE SHARE ANALYSIS OF CENTRAL LAB MARKET FOR SPECIMEN MANAGEMENT AND STORAGE, BY COUNTRY 2021 AND 2031(%)
FIGURE 15. COMPARATIVE SHARE ANALYSIS OF CENTRAL LAB MARKET FOR OTHERS, BY COUNTRY 2021 AND 2031(%)
FIGURE 16. CENTRAL LAB MARKET, BY END USER, 2021(%)
FIGURE 17. COMPARATIVE SHARE ANALYSIS OF CENTRAL LAB MARKET FOR PHARMACEUTICAL COMPANIES, BY COUNTRY 2021 AND 2031(%)
FIGURE 18. COMPARATIVE SHARE ANALYSIS OF CENTRAL LAB MARKET FOR BIOTECHNOLOGY COMPANIES, BY COUNTRY 2021 AND 2031(%)
FIGURE 19. COMPARATIVE SHARE ANALYSIS OF CENTRAL LAB MARKET FOR OTHERS, BY COUNTRY 2021 AND 2031(%)
FIGURE 20. CENTRAL LAB MARKET BY REGION, 2021
FIGURE 21. U.S. CENTRAL LAB MARKET, 2021-2031 ($MILLION)
FIGURE 22. CANADA CENTRAL LAB MARKET, 2021-2031 ($MILLION)
FIGURE 23. MEXICO CENTRAL LAB MARKET, 2021-2031 ($MILLION)
FIGURE 24. GERMANY CENTRAL LAB MARKET, 2021-2031 ($MILLION)
FIGURE 25. FRANCE CENTRAL LAB MARKET, 2021-2031 ($MILLION)
FIGURE 26. UK CENTRAL LAB MARKET, 2021-2031 ($MILLION)
FIGURE 27. ITALY CENTRAL LAB MARKET, 2021-2031 ($MILLION)
FIGURE 28. SPAIN CENTRAL LAB MARKET, 2021-2031 ($MILLION)
FIGURE 29. REST OF EUROPE CENTRAL LAB MARKET, 2021-2031 ($MILLION)
FIGURE 30. JAPAN CENTRAL LAB MARKET, 2021-2031 ($MILLION)
FIGURE 31. CHINA CENTRAL LAB MARKET, 2021-2031 ($MILLION)
FIGURE 32. INDIA CENTRAL LAB MARKET, 2021-2031 ($MILLION)
FIGURE 33. AUSTRALIA CENTRAL LAB MARKET, 2021-2031 ($MILLION)
FIGURE 34. SOUTH KOREA CENTRAL LAB MARKET, 2021-2031 ($MILLION)
FIGURE 35. REST OF ASIA-PACIFIC CENTRAL LAB MARKET, 2021-2031 ($MILLION)
FIGURE 36. BRAZIL CENTRAL LAB MARKET, 2021-2031 ($MILLION)
FIGURE 37. SAUDI ARABIA CENTRAL LAB MARKET, 2021-2031 ($MILLION)
FIGURE 38. SOUTH AFRICA CENTRAL LAB MARKET, 2021-2031 ($MILLION)
FIGURE 39. REST OF LAMEA CENTRAL LAB MARKET, 2021-2031 ($MILLION)
FIGURE 40. TOP WINNING STRATEGIES, BY YEAR
FIGURE 41. TOP WINNING STRATEGIES, BY DEVELOPMENT
FIGURE 42. TOP WINNING STRATEGIES, BY COMPANY
FIGURE 43. PRODUCT MAPPING OF TOP 10 PLAYERS
FIGURE 44. COMPETITIVE DASHBOARD
FIGURE 45. COMPETITIVE HEATMAP: CENTRAL LAB MARKET
FIGURE 46. TOP PLAYER POSITIONING, 2021
FIGURE 47. EUROFINS SCIENTIFIC: NET REVENUE, 2019-2021 ($MILLION)
FIGURE 48. EUROFINS SCIENTIFIC: REVENUE SHARE BY SEGMENT, 2021 (%)
FIGURE 49. ICON PLC: NET REVENUE, 2020-2022 ($MILLION)
FIGURE 50. ICON PLC: REVENUE SHARE BY REGION, 2022 (%)
FIGURE 51. MEDPACE: NET REVENUE, 2019-2021 ($MILLION)
FIGURE 52. MEDPACE: REVENUE SHARE BY REGION, 2021 (%)
FIGURE 53. IQVIA INC.: NET REVENUE, 2020-2022 ($MILLION)
FIGURE 54. IQVIA INC.: REVENUE SHARE BY SEGMENT, 2022 (%)
FIGURE 55. IQVIA INC.: REVENUE SHARE BY REGION, 2022 (%)
FIGURE 56. FRONTAGE LABS: NET REVENUE, 2019-2021 ($MILLION)
FIGURE 57. FRONTAGE LABS: REVENUE SHARE BY SEGMENT, 2021 (%)
FIGURE 58. FRONTAGE LABS: REVENUE SHARE BY REGION, 2021 (%)
FIGURE 59. LABORATORY CORPORATION OF AMERICA HOLDINGS: NET REVENUE, 2019-2021 ($MILLION)
FIGURE 60. LABORATORY CORPORATION OF AMERICA HOLDINGS: REVENUE SHARE BY SEGMENT, 2021 (%)
FIGURE 61. LABORATORY CORPORATION OF AMERICA HOLDINGS: REVENUE SHARE BY REGION, 2021 (%)

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us